Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Minimized Time to Beam in Patients With High Grade Gliomas
This study is not yet open for participant recruitment.
Verified by Alberta Cancer Board, May 2007
Sponsored by: Alberta Cancer Board
Information provided by: Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00469534
  Purpose

A Pilot Study Evaluating Minimized Time to Beam Hypofractionated IMRT with PET Assisted Target Definition in Patients with High Grade Gliomas

The aim of this pilot project is to explore the feasibility of combining a simple conformal plan (Phase I) with an IMRT treatment approach (Phase II) for high grade glioma patients with the aim of starting the RT as soon as possible following the patient's first outpatient visit (thus, minimized 'time to beam'). It is hoped that the rapid treatment start with the initial 3D CRT plan will lessen clinical deterioration due to the growth of these aggressive tumours. The use of Linac-based IMRT in Phase II of the patient's treatment plan will maintain the benefit of the sophistication of IMRT.

Using novel PET imaging we also hope to better characterize regions of glioma cells thus producing more optimized planning target volumes (PTVs) for each patient and decreasing the volume of normal brain irradiated with the aim of minimizing radiation toxicities. Hopefully this planning and treatment approach will provide an improvement in the quality of life and outcome for high grade glioma patients.


Condition Intervention
High Grade Glioma
Procedure: IMRT

MedlinePlus related topics: Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment
Official Title: A Pilot Study Evaluating Minimized Time to Beam Hypofractionated IMRT With PET-Assisted Target Definition in Patients With High Grade Gliomas

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:
  • Time from initial OPD visit to start of RT compared with historical controls receiving helical tomotherapy base IMRT (Time to Beam).

Secondary Outcome Measures:
  • Overall survival, disease-free survival, patterns of recurrence, toxicity, quality of life, number of patients who complete treatment.

Estimated Enrollment: 25
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histopathologically-confirmed high grade glioma
  • 18+ years of age
  • no prior radiation therapy to the brain
  • no active prior malignancy
  • KPS greater or equal to 70
  • singed study-specific consent form

Exclusion Criteria:

  • no histopathologically confirmation of high grade glioma
  • less than 18 years of age
  • prior radiation therapy to the brain
  • active prior malignancy
  • KPS less than 70
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469534

Contacts
Contact: Christy Bartoshewski, RN 780-577-8029 christyg@cancerboard.ab.ca

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
Alberta Cancer Board
Investigators
Principal Investigator: Albert Murtha, MD Alberta Cancer Board
  More Information

Study ID Numbers: CNS-9-0039
Study First Received: May 2, 2007
Last Updated: May 2, 2007
ClinicalTrials.gov Identifier: NCT00469534  
Health Authority: Canada: Health Canada

Keywords provided by Alberta Cancer Board:
minimized time to beam
hypofractionated 3D CRT plus IMRT
PET-scan

Study placed in the following topic categories:
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Glioma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial

ClinicalTrials.gov processed this record on January 16, 2009